Life Science REIT Plc: Key Disclosure and Position Analysis

Key Information Overview
Full name of discloser: Rathbones Group Plc
Name of offeror/offeree: Life Science REIT Plc
Date position held/dealing undertaken: This reflects the latest practicable date prior to the disclosure on the report date.
Disclosures related to interests: No other buy offers or disclosures have been conducted in relation to this offer.
Positions of the Person Making the Disclosure
Investor parties must provide a detailed breakdown of their associated interests and positions that may impact the relevant securities reported.
The following are categorized as interests and short positions in relation to the relevant securities:
Relevant Securities Disclosure
Class of Relevant Security: 1p Ordinary Shares
Owned and/or Controlled Relevant Securities: Rathbones Group Plc holds a significant number of 51,319,063 shares, representing 14.66% of the total.
Total Interests: This total reflects the cumulative shares held by Rathbones Group Plc within Life Science REIT Plc.
Dealing Activities
This section encompasses any transactions executed by the entities involved, specifically focusing on sales, purchases, and derivative transactions.
Purchases and Sales
In a recent transaction, sales of 9,500 shares of 1p Ordinary Shares were made at a price of 43.2503p each.
Summary of Cash-Settled Transactions
Details pertaining to any cash-settled derivatives remain to be updated, as no specific actions have been conducted.
Other Relevant Information
Any further disclosures will consider the nature of dealing arrangements and how they may influence market operation.
No special arrangements or options have been uncovered that could serve to incentivize further trading or engagement, establishing a clear framework for all existing interests.
Contact Information
For any inquiries or clarifications regarding these disclosures, please reach out to:
Contact Name: Chinwe Enyi – Compliance Department
Telephone Number: 0151 243 7053
For additional support, consider contacting the Panel’s Market Surveillance Unit directly at +44 (0)20 7638 0129.
Frequently Asked Questions
What is the significance of the 8.3 forms?
The form details significant shareholders' interests in securities, ensuring transparency in financial dealings within the market.
Who disclosed this information?
This information was disclosed by Rathbones Group Plc, the party with interests in Life Science REIT Plc’s shares.
What does it mean to hold 14.66% of securities?
Holding 14.66% implies significant influence over company decision-making and voting rights, making it a crucial interest to disclose.
Are there any agreements related to voting rights?
No agreements affecting voting rights have been noted in this disclosure.
Who can be contacted for additional information?
Chinwe Enyi from the Compliance Department is the point of contact for this disclosure, reachable via phone at 0151 243 7053.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.